Puration Inc (OTCMKTS:PURA) has announced the takeover of Telluride Health Company from Priority Aviation Inc (OTCMKTS:PJET). The company will merge the operations of Telluride with its cannabis beverage business.
The takeover is in line with the spin-off of AmeriCanna Cafe Business of North American Cannabis Holdings Inc (OTCMKTS:USMJ). Priority Aviation Inc has acquired AmeriCanna Cafe Business from North American Cannabis Holdings. Following the sell-off, Priority Aviation will offer dividends in the form of PJET shares to the shareholders of North American Cannabis Holdings.
President of Telluride Health Company, Yasmine Acebo said he is very happy about the merger with Puration Inc. The company will leverage the expertise and experience of Puration to sell its Telluride Happy Water, which is a brainchild of college students. The Telluride water is developed to enhance the experience of cannabis.
Chief Executive Officer of Puration Inc., Brian Shibley said the team at Telluride Health Company has developed a unique product that has no competitor. There is a great demand for Telluride Happy Water, which is expected to reach the shelves by the end of 2018. Telluride Happy water in rich in dissolved oxygen to offer great benefit to the consumers.
Market for Cannabis infused Edibles is expected at $2.3 Billion in 2018
The market for cannabis infused edibles is expected to reach $2.3 billion in 2018. According to Brightfield, a market research firm, the market for Cannabis infused edibles is expected to reach $5.3 billion in the forthcoming 5 years.
ACI Conglomerated Holds a Majority Stake in Puration Inc
ACI Conglomerated (ACI) owns a majority stake in Puration Inc. It also holds a stake in North American Cannabis Holdings. ACI is planning to acquire a controlling stake in Nouveau Life Pharmaceuticals Inc (OTCMKTS:NOUV).
Nouveau Life Pharmaceuticals Inc Inks Pact with Puration Inc to Form A JV to produce cannabis pharmaceutical products
Puration Inc has signed an accord with Nouveau Life Pharmaceuticals Inc to create a joint venture that will engage in the development of cannabis pharmaceutical products. The companies are planning to capitalize on the burgeoning demand for cannabis pharmaceuticals. The market for cannabis pharmaceutical products is expected to reach $50 billion in 2029.